Streetbeat News

Regulatory

ABEO

Abeona Therapeutics' stock trades lower following the FDA's issuance of a Complete Response Letter for its Biologics License Application for pz-cel, aimed at treating recessive dystrophic epidermolysis bullosa.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:59 pm

PXS

Pyxis Tankers Inc has filed with the SEC for a mixed shelf offering, allowing it to issue various securities up to a total value of $100 million. This strategic move could provide the company with flexible financing options for future growth, acquisitions, or debt management.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:52 pm

ASST

Asset Entities received a notice from Nasdaq on April 18 regarding delisting or failure to satisfy continued listing rules, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:49 pm

FRLA

Fortune Rise Acquisition Corp. (FRLA) received a Nasdaq notice on April 16 for failing to regain compliance with the public holders rule during the extension period. The company has requested a hearing, as per an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:49 pm

JAN

JanOne Inc received a notice from Nasdaq on April 16 indicating that the company does not currently comply with Nasdaq's Listing Rule 5550(b)(1), according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:48 pm

CURI

CuriosityStream Inc. received a letter from Nasdaq on April 19, indicating that the company has regained compliance with the Nasdaq's minimum bid price rule, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:46 pm

FORD

Forward Industries Inc. has been granted an extension by a Nasdaq panel to meet the Nasdaq's listing requirements. The company now has until July 9, 2024, to comply with the $1.00 bid price rule and the $2.5 million stockholders' equity rule, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:45 pm

AZTR

Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company, announced preclinical data for its ATR-12 candidate for Netherton syndrome, demonstrating superior LEKTI delivery and significant reduction in IL-36g, a pro-inflammatory cytokine. The data will be presented at ASGCT in Baltimore, MD, showcasing the potential of engineered Staphylococcus epidermidis as a protein delivery system for treating skin diseases. Azitra has an open IND for a Phase 1b clinical trial in adult patients with Netherton syndrome.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:40 pm

BKYI

BIO-key International, Inc. has received a notification letter from Nasdaq indicating that the company is not in compliance with Nasdaq's listing requirements. The specific details of the non-compliance were not disclosed in the notification.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:32 pm

VYGR

Voyager Therapeutics announced its plan to present translational data for its intravenous-delivered, central nervous system (CNS) gene therapy programs, which are advancing toward clinical trials, at the ASGCT 27th Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 8:31 pm